Vaccines and Biodefense

January 29, 2013

Project BioShield seeks to expand the U.S. stockpile of medical countermeasures for potential...

September 18, 2012

William Schaffner, MD, the immediate past president of the National Foundation for Infectious...

June 17, 2012

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have...

April 27, 2012

In recognition of National Infant Immunization Week, Dr. Yabo Beysolow, Medical Officer at the...

Letters, Testimony & Comments

July 1 2015
On June 15, 2015, the Department of Defense's (DoD's) Joint Project Manager-Medical Countermeasure Systems (JPM-MCS) held a co-located Industry Day in conjunction with the BIO Convention in Philadelphia, Pennsylvania. The MCS Industry Day focused on industry feedback related to the DoD's proposed use of an Other Transaction Authority (OTA) contracting mechanism. 
March 7 2014
On March 7, 2014, BIO submitted comments to the U.S. Office of Personnel Management (OPM) regarding OPM’s February 4, 2014 Multi-State Plan (MSP) Program Call Letter. BIO’s comments address the critical nature of the Affordable Care Act’s immunization coverage standard.
February 25 2014
BIO joined with the American Pharmacists Association (APhA), Association of State and Territorial Health Officials (ASTHO), Immunization Action Coalition (IAC), Merck, and the National Association of County and City Health Officials (NACCHO) to submit comments to the Centers for Medicare and Medicaid Services (CMS) regarding the February 4, 2014 Draft Letter to Issuers in the Federally-facilitated Marketplaces. 
December 19 2013
BIO submitted comments on the Centers for Medicare and Medicaid Services' (CMS’s) Federally Qualified Health Center (FQHC) Prospective Payment System (PPS) proposed rule, specifically as it relates to vaccine coverage for Medicare beneficiaries and reimbursement for vaccines under Medicare Part B.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.

Press Releases

January 21 2016
Washington, D.C. (January 21, 2016) – The Biotechnology Innovation Organization (BIO) applauds the Industry Declaration on Combating Antimicrobial Resistance, signed by 85 biopharmaceutical and diagnostic companies and released today at the World Economic Forum in Davos, Switzerland.
April 29 2015
Washington, D.C. (April 29, 2015) – The Biotechnology Industry Organization (BIO) today releases the following statement on the 21st Century Cures Initiative discussion draft shared by Chairman Fred Upton (R-MI), Rep. Diana DeGette (D-CO), Rep. Frank Pallone, Jr. (D-NJ), Rep. Joe Pitts (R-PA), and Rep. Gene Green (D-TX). 
February 6 2015
Bill would encourage vaccine research and benefit public health Washington, D.C. (February 6, 2015) – The Biotechnology Industry Organization (BIO) applauds the introduction of the Vaccine Access, Certainty, and Innovation Act of 2015. Sponsored by Representatives Renee Ellmers (R-NC) and G.K. Butterfield (D-NC), the Act is expected to be an important part of the Energy & Commerce Committee’s 21st Century Cures Initiative and would modernize the discovery, development, and delivery of vaccines. 
December 9 2014
Washington, D.C. (December 9, 2014) – The Biotechnology Industry Organization (BIO) applauds today’s declaration by Health and Human Services Secretary Sylvia M. Burwell under the Public Readiness and Emergency Preparedness (PREP) Act which will help advance the development and availability of experimental Ebola vaccines. The declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of three experimental Ebola vaccines.
December 4 2014
Washington, D.C. (December 4, 2014) – Today marks the inaugural meeting of the Blue Ribbon Study Panel on Biodefense, a bipartisan panel co-chaired by former Senator Joe Lieberman and former Governor and Homeland Security Secretary Tom Ridge. Panelists former Senator Tom Daschle, former Secretary of Health and Human Services Donna Shalala, former US Homeland Security Advisor Kenneth Wainstein, and Biotechnology Industry Organization (BIO) President and CEO and former Representative Jim Greenwood. The study will be directed by Dr. Robert Kadlec, former special assistant to the President for homeland security and senior director for biological defense policy in the White House Homeland Security Council.